中国继续医学教育
中國繼續醫學教育
중국계속의학교육
China Continuing Medical Education
2015年
26期
133-134
,共2页
左卡尼汀%促红细胞生成素%慢性肾衰竭%贫血%微炎症
左卡尼汀%促紅細胞生成素%慢性腎衰竭%貧血%微炎癥
좌잡니정%촉홍세포생성소%만성신쇠갈%빈혈%미염증
L-carnitine%EPO%CRP%Anemia%Microinlfammatory
目的:观察左卡尼汀联合促红细胞生成素(EPO)对维持性血液透析患者贫血和微炎症的影响。方法50例慢性肾衰竭维持性血液透析患者随机分为治疗组和对照组,对照组单独给予皮下注射EPO治疗,治疗组在EPO的基础上静脉注射左卡尼汀。观察两组患者治疗前后RBC、Hb、Hct以及CRP和血白蛋白的变化。结果两组患者治疗后RBC、Hb以及Hct水平比治疗前均升高,且治疗组患者RBC、Hb以及Hct的升高水平高于对照组;治疗组血清CRP的水平均较治疗前下降,血白蛋白水平升高,而对照组治疗前后血清CRP以及血白蛋白水平均未发生明显改变。结论左卡尼汀联合 EP0能改善维持性血液透析患者的贫血以及微炎症状态。
目的:觀察左卡尼汀聯閤促紅細胞生成素(EPO)對維持性血液透析患者貧血和微炎癥的影響。方法50例慢性腎衰竭維持性血液透析患者隨機分為治療組和對照組,對照組單獨給予皮下註射EPO治療,治療組在EPO的基礎上靜脈註射左卡尼汀。觀察兩組患者治療前後RBC、Hb、Hct以及CRP和血白蛋白的變化。結果兩組患者治療後RBC、Hb以及Hct水平比治療前均升高,且治療組患者RBC、Hb以及Hct的升高水平高于對照組;治療組血清CRP的水平均較治療前下降,血白蛋白水平升高,而對照組治療前後血清CRP以及血白蛋白水平均未髮生明顯改變。結論左卡尼汀聯閤 EP0能改善維持性血液透析患者的貧血以及微炎癥狀態。
목적:관찰좌잡니정연합촉홍세포생성소(EPO)대유지성혈액투석환자빈혈화미염증적영향。방법50례만성신쇠갈유지성혈액투석환자수궤분위치료조화대조조,대조조단독급여피하주사EPO치료,치료조재EPO적기출상정맥주사좌잡니정。관찰량조환자치료전후RBC、Hb、Hct이급CRP화혈백단백적변화。결과량조환자치료후RBC、Hb이급Hct수평비치료전균승고,차치료조환자RBC、Hb이급Hct적승고수평고우대조조;치료조혈청CRP적수평균교치료전하강,혈백단백수평승고,이대조조치료전후혈청CRP이급혈백단백수평균미발생명현개변。결론좌잡니정연합 EP0능개선유지성혈액투석환자적빈혈이급미염증상태。
Objective To observer the effect of L-carnitine combined with EPO on maintenance hemodialytic patients with anemia and microinlfammatory.MethodsSelected 50 cases of Renal Failure patients (CFP) on maintenance hemodialytic were divided into treatment group and control group randomly, the control group were given EPO intravenously alone, the treatment group were treated additionally with L-carnitine by intravenous injection. To observe the changes of RBC, Hb and Hct, also CRP and serum albumin before and after the different treatment.Results The levels of RBC, Hb and Hct increased in both groups than that before treatment, and the treatment group improved more signiifcantly the level of CRP decreased and the level of serum albumin increased after treatment in treatment group, but the levels of the two were no signiifcant difference in control group.Conclusion The combined treatment of L-carnitine and EPO can significantly improve the anemia and microinflammatory in maintenance hemodialytic patients.